Cellebrite DI Ltd

Cellebrite provides digital forensics software that helps law enforcement, governments and enterprises access and analyze data from devices and cloud sources. We added the company to the GardenSM prior to the launch of Genesis, its agentic AI platform for digital investigations. We believe Genesis has the potential to meaningfully accelerate growth over time by improving investigator productivity, expanding the company’s addressable market and positioning Cellebrite as an early leader in AI-powered digital forensics.

Cellebrite is positioned to benefit from AI advancements, contrary to the market's perception of it as an AI loser. The company recently launched its first AI product, Genesis, which is designed to enhance investigative processes. Management believes that this product could double Cellebrite's addressable market. Despite current revenue guidance excluding AI contributions, the potential for significant growth exists as the product gains traction. With a history of 20%+ recurring revenue growth and a solid balance sheet, the company trades at an attractive multiple, suggesting that as AI revenue materializes, it could transition from an AI loser to an AI winner, leading to multiple expansion and a higher share price.

Cellebrite's shares were down over 16% in 2025, despite a 19% increase in annual recurring revenue (ARR) and a 30% growth in free cash flow. The market fears that AI and 'vibe coding' could lower software creation barriers, leading to valuation compression. However, I believe Cellebrite is more likely to benefit from AI than be harmed. The company has significant resources dedicated to security research, making it unlikely for government agencies to replace it with unproven alternatives. Management is confident that growth will reaccelerate in 2026, projecting ARR growth of over 20%. With a stable customer base and a strong market position, the risk of meaningful disruption from AI appears low.

Cellebrite operates in a niche with significant barriers to entry, leveraging its hardware-enabled software solution that has become synonymous with digital forensics. The company has a defensible moat due to its extensive exploit library and the technical expertise required for device unlocking and data extraction. With the introduction of AI functionalities, such as the Guardian Investigate product, Cellebrite is poised for growth by expanding its total addressable market. Its valuation is compelling, trading at a significant discount to the broader market while maintaining strong free cash flow margins and a robust net cash position.

Cellebrite (CLBT) is a digital forensics enterprise software company that is currently undervalued due to a general decline in software multiples. Despite this, Cellebrite's unique suite of products offers high value to law enforcement agencies, which face increasing case backlogs and a shortage of skilled employees. The company is set to release investigative AI tools in January 2026, positioning it to benefit from the growing demand for technology in crime-solving. The CEO believes that recent U.S. legislation will turn current spending headwinds into tailwinds, leading to a resurgence in growth. With limited competition, high insider ownership, and a strong balance sheet, Cellebrite has a long runway for organic growth and profitability.

Cellebrite (CLBT) is a digital forensics enterprise software company that, despite being down for the year, is well-positioned to benefit from AI advancements. The company offers a suite of products that are essential for law enforcement agencies, which face increasing case backlogs and a shortage of technically skilled employees. With a 34% free cash flow margin and limited competition, Cellebrite's value proposition remains strong. The CEO anticipates that recent U.S. legislation will convert current spending headwinds into tailwinds, leading to a resurgence of growth in 2026. The company is also undergoing Fed Ramp approval, facilitating easier purchases by Federal agencies.

Cellebrite (CLBT) is a duopolistic 'Rule of 40+' compounder trading at a steep discount to software and government intelligence/cybersecurity peers. The market is underestimating CLBT’s transition into a full-blown 'case to closure' software platform. The revenue growth acceleration story of 2026 is expected to come into focus due to federal spending resurgence and successful cross-selling initiatives. The company has exceptional cash flow dynamics, converting 130-140% of EBITDA into free cash flow. With activist investors involved, the likelihood of a full sale within two years increases, and if growth re-accelerates, shares could see significant upside.

Cellebrite (CLBT) is a duopolistic 'Rule of 40+' compounder trading at a steep discount to software and government intelligence/cybersecurity peers. The market is underestimating CLBT’s transition into a full-blown 'case to closure' software platform. The revenue growth acceleration story of 2026 is expected to come into focus due to federal spending resurgence and successful product upgrades. The company has exceptional cash flow dynamics, converting 130-140% of EBITDA into free cash flow. With activist investors involved, the likelihood of a full sale increases, and if growth re-accelerates, shares could see significant upside.

Cellebrite DI is a software company providing a platform for digital investigation primarily for law enforcement customers. As a market leader in digital forensics, the company has made logical additions to its platform that should unlock incremental future growth at attractive profitability.

Cellebrite (CLBT), the leading provider of digital forensics software used by law enforcement and government agencies worldwide, reported results that were about as constructive as we could have hoped for given the stock’s 50% drop from earlier in the year. Management cut revenue guidance by just 1% and raised EBITDA guide by 2%, while ARR was trimmed by ~4% due primarily to federal budget timing issues. This leaves the stock positioned for potential beats in the back half of the year as federal contracts normalize. Importantly, gross margins remain exceptionally strong relative to software peers (subscription margins above 90%), billings growth has reaccelerated to 25% and now exceeds revenue and ARR growth, and free cash flow continues to outpace EBITDA by more than 30% thanks to low capex, favorable working capital dynamics, and R&D tax credits—underscoring CLBT’s pristine quality of earnings.